Vivanza Biosci.

Which are the latest news on Vivanza Biosci.?

Why is Vivanza Biosciences Ltd falling/rising?

As of 05-Sep, Vivanza Biosciences Ltd's stock price is at 1.75, showing a slight increase today but a significant year-to-date decline of 20.45% and an 87.33% drop over three years. The stock's moving averages and reduced investor participation indicate ongoing challenges despite the short-term gain.

As of 05-Sep, Vivanza Biosciences Ltd's stock price is currently at 1.75, reflecting a slight increase of 0.01 (0.57%). This rise can be attributed to its performance today, where it outperformed the sector by 0.36%. However, despite this short-term gain, the stock has shown a significant decline over longer periods, with a year-to-date drop of 20.45% and a staggering 87.33% decrease over the past three years. <BR><BR>Additionally, the stock's moving averages indicate that while it is currently higher than the 5-day moving average, it remains lower than the 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a longer-term downward trend. Furthermore, there has been a notable decline in investor participation, with delivery volume falling by 65.39% against the 5-day average, indicating reduced interest from investors. <BR><BR>In summary, while there is a minor uptick in the stock price today, the overall trend and investor participation suggest ongoing challenges for Vivanza Biosciences Ltd.

Who are in the management team of Vivanza Biosci.?

The management team of Vivanza Biosci includes Hemant Parikh (Director), Sunil Shah (Independent Director), Avinash G. Bhojwani (Company Secretary & Compliance Officer), Apeksha Vyas (Independent Director), and Jayendra Mehta (Managing Director).

The management team of Vivanza Biosci includes the following individuals:<BR><BR>1. **Hemant Parikh** - Director<BR>2. **Sunil Shah** - Independent Director<BR>3. **Avinash G. Bhojwani** - Company Secretary & Compliance Officer<BR>4. **Apeksha Vyas** - Independent Director<BR>5. **Jayendra Mehta** - Managing Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Vivanza Biosci. do?

Vivanza Biosciences Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, incorporated in 1982 and publicly listed since 1992. As of June 2026, it reported net sales of 9 Cr and a market cap of INR 7 Cr, with a P/E ratio of 15.00.

Overview:<BR>Vivanza Biosciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Vivanza Biosciences Ltd was incorporated in March 1982 as a Private Limited Company and transitioned to a Public Limited Company in May 1992. The company changed its name from Ivee Injectaa Limited to Vivanza Biosciences Limited in 2015, following setbacks in the parenteral industry during the recessionary trends of 1999-2000. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 9 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00 <BR>Industry P/E: 31 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.32 <BR>Return on Equity: 9.17% <BR>Price to Book: 1.59 <BR><BR>Contact Details:<BR>Address: 403 Sarthik 2 Opp Rajpath Club, S G Highway Ahmedabad Gujarat : 380054 <BR>Tel: 91-07405699869 <BR>Website: http://www.vivanzabiosciences.com

Who are the peers of the Vivanza Biosci.?

Vivanza Biosci.'s peers include Starsource Multi, Unjha Formul., Ortin Global, Beryl Drugs, Ganga Pharma., Brawn Biotech, Decipher Labs, Fabino Enter, and Shyama Computro. Unjha Formul. shows the best management and return metrics, while Vivanza Biosci. has average management risk and a 1-year return of -17.07%.

Peers: The peers of Vivanza Biosci. are Starsource Multi, Unjha Formul., Ortin Global, Beryl Drugs, Ganga Pharma., Brawn Biotech, Decipher Labs, Fabino Enter, and Shyama Computro.<BR><BR>Quality Snapshot: Excellent management risk is observed at Unjha Formul., while Average management risk is found at Vivanza Biosci. and the rest. Below Average management risk is noted for Ortin Global, Beryl Drugs, Ganga Pharma., Brawn Biotech, Decipher Labs, and Fabino Enter. Growth is Average at Vivanza Biosci., Below Average at Ortin Global, Beryl Drugs, Ganga Pharma., Brawn Biotech, Decipher Labs, and Fabino Enter, and does not qualify for Starsource Multi and Shyama Computro. Capital Structure is Good at Unjha Formul., Average at Ganga Pharma., and Below Average for the rest.<BR><BR>Return Snapshot: Unjha Formul. has the highest 1-year return at 10.70%, while Decipher Labs has the lowest at -48.50%, with Vivanza Biosci. showing a 1-year return of -17.07%. Additionally, the six-month returns are negative for Starsource Multi, Ortin Global, Ganga Pharma., Brawn Biotech, Decipher Labs, and Vivanza Biosci.

How big is Vivanza Biosci.?

As of 31st August, Vivanza Biosciences Ltd has a market capitalization of 7.00 Cr, with recent net sales of 116.26 Cr and a net profit of 0.46 Cr. The company has shareholder's funds of 4.36 Cr and total assets of 22.09 Cr as of March 2026.

As of 31st August, Vivanza Biosciences Ltd has a market capitalization of 7.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Vivanza Biosciences reported Net Sales of 116.26 Cr and a Net Profit of 0.46 Cr.<BR><BR>As of the latest annual period in March 2026, the company has Shareholder's Funds amounting to 4.36 Cr and Total Assets of 22.09 Cr.

Should I buy, sell or hold Vivanza Biosciences Ltd?

When is the next results date for Vivanza Biosciences Ltd?

The next results date for Vivanza Biosciences Ltd is August 1, 2026.

The next results date for Vivanza Biosciences Ltd is scheduled for August 1, 2026.

Are Vivanza Biosciences Ltd latest results good or bad?

Vivanza Biosciences Ltd's latest results are concerning, showing a net loss of ₹0.45 crores and an 85.94% drop in revenue quarter-over-quarter, despite a year-on-year revenue growth of 1,225%. The company's lack of profitability and negative operating margins raise doubts about its business sustainability, leading to a 5% decline in stock price post-announcement.

Vivanza Biosciences Ltd's latest results indicate a challenging situation for the company. In Q4 FY26, the company reported a net loss of ₹0.45 crores, which is a significant decline of 325% compared to the previous quarter. Additionally, revenue fell sharply by 85.94% quarter-over-quarter to ₹6.36 crores, although it did show an impressive year-on-year growth of 1,225% from ₹0.48 crores in Q4 FY25.<BR><BR>Despite the explosive year-on-year revenue growth, the company is currently loss-making and has negative operating margins of -3.77%. This raises concerns about the sustainability of its business model and its ability to convert revenue growth into consistent profitability. The stock price has also reacted negatively, dropping 5% following the results announcement, and it has declined 13.64% year-to-date.<BR><BR>Overall, while there are signs of significant revenue expansion, the lack of profitability and operational challenges suggest that the latest results are more concerning than positive. Investors are advised to be cautious given the company's current financial instability and volatility.

How has been the historical performance of Vivanza Biosci.?

Vivanza Biosci. experienced significant financial declines, reporting net sales of 7.42 Cr in March 2025, down from 27.84 Cr in March 2024, resulting in a loss with a profit after tax of -0.67 Cr. The company faced negative cash flow and decreased total assets and liabilities during this period.

Answer:<BR>The historical performance of Vivanza Biosci. shows significant fluctuations in its financial metrics over the years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>Vivanza Biosci. reported net sales of 7.42 Cr in March 2025, a sharp decline from 27.84 Cr in March 2024 and 17.81 Cr in March 2023. The total operating income mirrored this trend, dropping to 7.42 Cr in March 2025 from 27.84 Cr in the previous year. Total expenditure also decreased to 7.79 Cr in March 2025 from 26.77 Cr in March 2024. Operating profit (PBDIT) turned negative at -0.31 Cr in March 2025, following a profit of 1.12 Cr in March 2024. Consequently, the profit before tax fell to -0.67 Cr in March 2025, down from 0.70 Cr in March 2024, leading to a profit after tax of -0.67 Cr compared to a profit of 0.55 Cr in the prior year. The company's total liabilities decreased to 16.45 Cr in March 2025 from 19.50 Cr in March 2024, while total assets also fell to 16.45 Cr from 19.50 Cr. Cash flow from operating activities was negative at -2.00 Cr in March 2025, contrasting with a positive cash flow of 2.00 Cr in March 2024. Overall, the financial performance indicates a challenging year for Vivanza Biosci., marked by declining revenues and profitability.

Who are the top shareholders of the Vivanza Biosci.?

The top shareholders of Vivanza Biosci are Parth Hemant Parikh with 19.77%, Ashoka Metcast Limited with 3.85%, and individual investors who collectively own 73.69%. There are no institutional investors or mutual funds involved.

The top shareholders of Vivanza Biosci include Parth Hemant Parikh, who holds the highest stake at 19.77%. The next significant public shareholder is Ashoka Metcast Limited, with a holding of 3.85%. Additionally, individual investors collectively hold a substantial 73.69% of the company's shares. There are no institutional investors or mutual funds involved in the shareholding.

Is Vivanza Biosci. overvalued or undervalued?

As of May 13, 2025, Vivanza Biosci. is considered risky and overvalued due to a negative PE ratio of -9.52, an EV to EBIT of -18.05, and a ROE of -16.92%, significantly underperforming compared to its peers, with a 59.33% decline in stock performance over the past year.

As of 13 May 2025, the valuation grade for Vivanza Biosci. has moved from attractive to risky, indicating a significant shift in the company's perceived value. The company is currently considered overvalued, given its negative PE ratio of -9.52 and an EV to EBIT of -18.05, which highlight underlying financial distress. Additionally, the ROE stands at -16.92%, further emphasizing the challenges faced by the company.<BR><BR>In comparison to its peers, Vivanza Biosci. lags significantly behind. For instance, Altius Telecom, rated very attractive, boasts a PE ratio of 52.97, while other peers like Embassy Office REIT and Inventurus Knowledge are categorized as very expensive with PE ratios of 23.06 and 56.63, respectively. The stark contrast in these ratios suggests that Vivanza Biosci. is not only underperforming but also carries a higher risk profile relative to its industry counterparts. Recent stock performance shows a decline of 59.33% over the past year, contrasting sharply with the Sensex's return of 7.65%, reinforcing the notion of overvaluation.

What is the technical trend for Vivanza Biosci.?

As of June 4, 2025, Vivanza Biosci's trend has shifted to mildly bearish, indicated by daily moving averages and weekly RSI, despite a mildly bullish weekly MACD, with overall indicators suggesting weakness and significant underperformance over the past year.

As of 4 June 2025, the technical trend for Vivanza Biosci has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly RSI showing bearish momentum. Although the weekly MACD is mildly bullish, the overall indicators, including the Bollinger Bands and KST on a monthly basis, suggest weakness. The Dow Theory indicates no clear trend in both weekly and monthly perspectives. The stock has underperformed significantly over the past year, further supporting the bearish outlook.

Has Vivanza Biosci. declared dividend?

No Dividend History Available